The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | Allogeneic transplantation for CMML from the Latin American perspective
In this video, Fernando Barroso Duarte, MD, Federal University of Ceará, Clinical Hospital, Fortaleza, Brazil, provides insight into the status of allogeneic stem cell transplantation (alloSCT) for chronic myelomonocytic leukemia (CMML) in Latin America, highlighting some challenges that exist in the diagnosis and access to transplant. Dr Duarte emphasizes the need to improve access to alloSCT, the only curative approach available for patients, and to enhance diagnosis, stratification, and transplantation options in Latin American centers. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It’s a very interesting situation because we have a problem specifically with the diagnosis. It’s the first difficulty, the challenge that you have. And after the diagnosis, we have another situation that is about the stratification of these patients because the access to the NGS and the molecular stratification is sometimes a problem – only about 20% of the centers have access...
It’s a very interesting situation because we have a problem specifically with the diagnosis. It’s the first difficulty, the challenge that you have. And after the diagnosis, we have another situation that is about the stratification of these patients because the access to the NGS and the molecular stratification is sometimes a problem – only about 20% of the centers have access.
And after this, another problem, you have in Latin America 20 countries that have bone marrow transplantation. And we made a survey and you have the answers from 12 centers. You have 14 centers that do have bone marrow transplantation. And from these 12 centers, only 50% perform unrelated donors, transplant with unrelated donors. And that you have the restriction of the options for these patients.
And then another very important thing is that the median age of the patients from Latin America is different from the United States and Europe. The patients with the median age in Brazil is like 61 years, and in whole Latin America is about 55 years. It’s probably related with the exposure of these patients to pesticides or something related with the occupational realities of these patients.
And then we should try to improve the access to bone marrow transplantation because it’s the only curative approach that we have. And we should discuss this with the centers, improving the diagnosis, stratification, and access to the bone marrow transplantation.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
